ELM-1 is an ongoing, open-label, multicenter Phase 1 trial to investigate the safety and tolerability of odronextamab in patients with CD20+ B-cell malignancies previously treated with CD20-directed ...
We're rolling into Week 13 of the 2024 NFL season, and league insiders Jeremy Fowler and Dan Graziano are here to break down the biggest questions, latest news and notable buzz heading into the ...